AN2 THERAPEUTICS INC (ANTX)
Health Care · Clinical-stage biopharmaceutical / small-molecule drug development · NASDAQ
Clinical-stage biotech leveraging a proprietary boron chemistry platform to develop novel small-molecule therapeutics for hematologic, infectious, and oncologic diseases.
What AN2 THERAPEUTICS INC does
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from its proprietary boron chemistry platform. The company's development pipeline spans hematologic diseases, infectious diseases, and oncology, with multiple Phase 2 studies expected to initiate in 2026. AN2 is advancing several product candidates including epetraborole for polycythemia vera and M. abscessus complex lung disease, and AN2-502998 for Chagas disease.
Themes: ["Boron chemistry platform"]
Fundamentals
- Price$4.63 as of 2026-07-09 close
- Market cap$167M as of 2026-07-10
- 1-year return+316.0% as of 2026-07-09 close
- ROE-52.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta-0.99 as of 2026-07-10
Key risks (from latest filing)
["Drug development is uncertain and costly; the company cannot reasonably estimate nature, timing, or costs required to complete development of product candidates or when revenue from commercialization will be generated."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.